Lesaka’s Q2 FY2026 Results: Lesaka achieves mid-point of its profitability guidance and reaffirms its FY2026 full year guidance JOHANNESBURG, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the second quarter of fiscal 2026 (“Q2 2026”). Q2 2026 performance1:All growth rates are year-on-year between Q2 FY2026 and Q2 FY2025. Group LevelUSD(In thousands, except per share data) ZAR(In thousands, except per share data) Q2 FY26 Q2 FY25 Q2 FY26 Q2 FY25 YoY%Revenue178,734 176,216 3,058,191 3,155,758 (3%)Net Revenue(2)93,403 77,0...
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Fireside ChatFebruary 11, 2026, at 10:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFireside ChatFebruary 25, 2026, at 10:00 am ET Live webcasts ...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i) non-qualified stock options to purchase a total of 120,000 shares of the Company’s common stock...
Standard BioTools Completes Sale of SomaLogic to Illumina Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed the previously announ...
We are taking 3Q25 results and the most recent cNPS data and laying out our latest thinking and forecasts ahead of 4Q results. We expect 4Q results and attendant 2026 guidance to contain material information value for investors and we wanted to share our latest forecasts, data, and trends as a starting point as we navigate this impactful season.
Synaptics to Report Second Quarter Fiscal 2026 Results on February 5, 2026 SAN JOSE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced that it will report financial results for the second quarter of fiscal 2026 on Thursday, February 5, 2026, after the market closes. The Company will host a corresponding conference call for analysts and investors at 2:00 p.m. PT (5:00 p.m. ET), to discuss the results. To participate on the live call, analysts and investors should pre-register at . Registrants will receive dial-in information and a unique passcod...
Earlier this month DISH filed an antitrust complaint against DIS in the latest chapter of a long running dispute over DIS’s efforts to create new sports bundles and DISH’s efforts to create new options for how its customers access programming over its platform. In this note we explore the implications of the battle, how it might affect the flexibility of content and distribution in seeking to adjust to thrive in the media world to come, and what it could tell us about the direction of media and...
Synaptics to Participate at Upcoming Investor Conference Tuesday, January 13, 2026 SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced its participation in upcoming investor conference. Ken Rizvi, Chief Financial Officer, will present at the 28th Annual Needham Growth Conference on Tuesday, January 13, 2026 at 10:30 AM PT. To view the webcast or access a replay, please visit . About Synaptics Incorporated: Synaptics (Nasdaq: ) is driving innovation in AI at the Edge, bringing AI closer to end users and transforming how we engage with in...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuin...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on January 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 48,000 shares of the Company’s common stock a...
Synaptics Appoints Venkatesh (Venk) Nathamuni to Board of Directors SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) (“Company”) today announced that on December 29, 2025, its Board of Directors (“Board”) appointed Venkatesh (Venk) Nathamuni to serve as a member of the Company’s Board and as a member of its Audit Committee, with service commencing on January 1, 2026. Mr. Nathamuni has more than 30 years of leadership experience with deep expertise in corporate finance, strategy, mergers and acquisitions, investor relations, and public company governan...
Two Directors at Kingsway Financial Services Inc sold 49,229 shares at between 12.800USD and 13.324USD. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Synaptics Showcases Edge AI Innovations at CES 2026 Featuring Synaptics Astra™, Veros™, and Multimodal Sensing SAN JOSE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced that it will showcase a broad portfolio of AI-native processing, sensing, and connectivity technologies at CES 2026. These solutions demonstrate how intelligence at the Edge transforms real-world applications across consumer, industrial, smart home, and enterprise markets.As global demand grows for devices that can interpret their environment, make context-aware decisions, and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.